arrow
J

Julià Blanco

irsicaixa aids research institute
H指数:59
被引数:1.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

First-line dolutegravir/lamivudine in HIV-1 infection: lymph node penetration and reservoir decline in a randomized open-label clinical trial

HIV-1感染中一线多替拉韦/拉米夫定治疗:一项随机开放标签临床试验中的淋巴结渗透和病毒库下降

2026-10-020
OA
TARDBP as a regulator of HIV-1 assembly and infection: a review of targeting the viral capsid precursor Pr55Gag and limiting viral core entry

TARDBP作为HIV-1组装和感染的调控因子:靶向病毒衣壳前体Pr55Gag并限制病毒核心进入的综述

2026-03-030
OAAI
Immune Durability and Breakthrough Infections 15 Months After SARS-CoV-2 Boosters in People over 65: The IMMERSION Study

SARS-CoV-2加强针接种后15个月的免疫持久性与突破性感染:IMMERSION研究

2025-08-230
PRE
A human-ACE2 knock-in mouse model for SARS-CoV-2 infection recapitulates respiratory disorders but avoids neurological disease associated with the transgenic K18-hACE2 model

人源ACE2基因敲入小鼠模型能够重现SARS-CoV-2感染导致的呼吸系统紊乱,但避免了与转基因K18-hACE2模型相关的神经疾病。

MBIO
IF4.7
2025-05-140
OA
Long-lasting antibody B-cell responses to SARS-CoV-2 three years after the onset of the pandemic

大流行开始三年后对SARS-CoV-2的长期抗体B细胞应答

2025-04-010
OAAI
Humoral and cellular immune responses after 6 months of a heterologous SARS-CoV-2 booster with the protein-based PHH-1V vaccine in a phase IIb trial

异种SARS-CoV-2加强针(蛋白基PHH-1V疫苗)在IIb期试验中接种6个月后的体液和细胞免疫应答

VACCINE
IF3.5
2025-02-011
OAAI
Impact of Dolutegravir Plus Lamivudine as First-line Antiretroviral Treatment on the Human Immunodeficiency Virus Type 1 Reservoir and Inflammatory Markers in Peripheral Blood

度鲁特韦联合拉米夫定一线抗逆转录病毒治疗对外周血人类免疫缺陷病病毒1型储库和炎症标志物的影响

2024-10-280
PRE
NSGS mice humanized with cord blood mononuclear cells show sustained and functional myeloid-lymphoid representation with limited graft-versus-host disease
2024-10-070
OAAI
Omicron XBB.1.16-Adapted Vaccine for COVID-19: Interim Immunogenicity and Safety Clinical Trial Results

Omicron XBB.1.16-适用于新型冠状病毒肺炎的疫苗: 临时免疫原性和安全性临床试验结果

2024-07-250
OAAI
Production and Immunogenicity of FeLV Gag-Based VLPs Exposing a Stabilized FeLV Envelope Glycoprotein

暴露稳定的FeLV包膜糖蛋白的基于FeLV Gag的vlp的产生和免疫原性

2024-06-190
OAAI
Prospective individual patient data meta-analysis of two randomized trials on convalescent plasma for COVID-19 outpatients (vol 13, 2583, 2022)

新型冠状病毒肺炎门诊患者恢复期血浆的两项随机试验的前瞻性个体患者数据荟萃分析 (第13卷,2583,2022)

2024-05-220
OAAI
Immunization with V987H-stabilized Spike glycoprotein protects K18-hACE2 mice and golden Syrian hamsters upon SARS-CoV-2 infection

V987H-stabilized刺突糖蛋白预防接种可保护SARS-CoV-2感染后的K18-hACE2小鼠和金叙利亚仓鼠

2024-03-210
OAAI
Immunisation efficacy of a stabilised SARS-CoV-2 spike glycoprotein in two geriatric animal models

稳定的SARS-CoV-2刺突糖蛋白在两种老年动物模型中的免疫功效

2024-02-271
OAAI